Since the 1990s, there have been clinical trials using genetically modified T cells. This has been possible due to advancements in gene delivery technology, allowing the creation of engineered T cells, including chimeric antigen receptor (CAR)-T cell therapies and other novel therapeutic approaches.
The synthetic biology technology used in the creation of CAR-T cells has enabled global, multi-center clinical trials, resulting in T cell immunotherapies with FDA, EMEA, Canada, Switzerland, Japan and Australia approvals. One such treatment, Kymriah™ from Novartis, has recently been approved for use in relapsed/refractory acute lymphoid leukemia in children and young adults, as well as in diffuse large B-cell lymphoma. However, the translation of these technologies from research bench to clinical application requires integrated scientific, engineering, and regulatory expertise.
New designs for genetically engineered T cells include switches and potency enhancements that will be required for targeting solid tumors. The road forward for wide patient access to these uniquely personal cellular therapies depends not only on scientific progress in targeting, gene modification and cellular manipulation, but also on meeting automation, engineering, and health policy changes.
In this expert webinar, Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, will discuss the clinical development of a unique CAR-T cell therapy and address the current healthcare challenges that impact the development of these therapies.
Watch this webinar to learn about:
The live webinar takes place on Monday, June 29, 2020 at:
Register to watch the full webinar here>>
SelectScience runs 3-4 webinars a month across various scientific topics, discover more of our upcoming webinars>>